News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: Final Data from Phase II Multi-Center Study Evaluating Combination of VIDAZA® and REVLIMID® in Higher-Risk MDS Patients Presented at American Society of Hematology


12/13/2011 6:50:59 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug. These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES